In the past few years, we've noticed that biotech products like TKIs are taking market share from chemo products and espcecially hormone therapies. This trend was reported on in the Oncology Report, citing Kalorama's market estimate by analyst Melissa Elder.
Of course it should be clear that pricing is part of the story behind revenue growth of biological approaches to cancer. Treatments for Avastin or Herceptin can add up to scores of thousands of dollars. Still, the success of these products commerically does indicate increasing effectiveness and acceptance by government agencies, payors, providers and patients.
